A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

BACKGROUND: Lenalidomide treatment in myelodysplastic syndrome (MDS) may lead to thrombocytopenia and dose reductions/delays. This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and its effects on the incidence of clinically significant thrombocytopenic events...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Eunice S, Lyons, Roger M, Larson, Richard A, Gandhi, Sunil, Liu, Delong, Matei, Carmen, Scott, Bart, Hu, Kuolung, Yang, Allen S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520696/
https://www.ncbi.nlm.nih.gov/pubmed/23190430
http://dx.doi.org/10.1186/1756-8722-5-71

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520696/
https://www.ncbi.nlm.nih.gov/pubmed/23190430
http://dx.doi.org/10.1186/1756-8722-5-71

Ejemplares similares